GLOBAL NUCLEAR MEDICINE &

RADIOPHARMACEUTICAL MARKET

Comprehensive Market Analysis & Strategic Forecast  |  2024 – 2032

Executive Summary

Western Market Research Intelligence is proud to publish its authoritative market intelligence report on the Global Nuclear Medicine and Radiopharmaceutical Market. The market was valued at USD 10.6 billion in 2024 and is projected to reach USD 27.4 billion by 2032, registering a robust compound annual growth rate (CAGR) of 12.6% over the eight-year forecast period. This remarkable expansion is powered by the convergence of a global cancer crisis demanding superior diagnostic and therapeutic precision, breakthrough approvals in targeted radionuclide therapy (TRT), the clinical and commercial validation of the theranostics paradigm, and transformative advances in isotope production technology.

Nuclear medicine harnesses the unique biological targeting properties of radioactive isotopes to diagnose disease at the molecular level through imaging modalities including positron emission tomography (PET) and single-photon emission computed tomography (SPECT), and to treat disease through targeted delivery of cytotoxic radiation directly to malignant cells via therapeutic radiopharmaceuticals. The field's central promise — delivering the right radiation to the right target at the right dose, while sparing healthy tissue — positions it as a cornerstone technology in the emerging era of precision oncology.

This report provides exhaustive analysis of market dynamics across diagnostic and therapeutic segments, isotope production infrastructure, the clinical pipeline of novel radiopharmaceutical agents, competitive intelligence across the global vendor landscape, and a detailed nine-year market forecast through 2032.

Key Market Findings

Market Valuation & Growth

•       Global nuclear medicine and radiopharmaceutical market valued at USD 10.6 billion in 2024; forecast to reach USD 27.4 billion by 2032 at a CAGR of 12.6%.

•       Therapeutic radiopharmaceuticals represent the fastest-growing product segment, projected to expand at a CAGR of 21.3% through 2032, driven by targeted radionuclide therapy (TRT) approvals.

•       North America leads with a 41% market share; Asia-Pacific is the fastest-growing region with a CAGR of 16.4%.

•       Oncology is the dominant application area, capturing 49.1% of total market revenue in 2024 and growing at a premium CAGR of 15.2%.

•       Lutetium-177 (Lu-177) is the fastest-growing isotope commercially, with revenue nearly tripling between 2022 and 2024 following multiple TRT approvals.

Theranostics: The Market-Defining Paradigm

•       Theranostics — the integration of diagnostic imaging and targeted radiotherapy using the same or paired molecular targets — is transforming oncology care delivery and reshaping pharmaceutical commercial strategies globally.

•       Novartis's Pluvicto (Lu-177-PSMA-617), approved by the FDA in March 2022 for metastatic castration-resistant prostate cancer (mCRPC), generated revenues exceeding USD 980 million in 2023, validating the commercial scale of TRT.

•       The PSMA theranostics axis — pairing F-18 PSMA PET imaging for patient selection with Lu-177 PSMA therapy for treatment — is being replicated across multiple cancer types including neuroendocrine tumours (NETs), glioblastoma, and breast cancer.

•       Somatostatin receptor (SSTR) theranostics via Ga-68 DOTATATE PET and Lu-177 DOTATATE therapy (Lutathera) represent the established blueprint for the emerging generation of multi-target theranostic programs.

Alpha Emitter Revolution

•       Targeted alpha therapy (TAT) using Actinium-225 (Ac-225) and Astatine-211 (At-211) is emerging as the next frontier in radiopharmaceutical oncology, with alpha particles delivering 5–10x higher linear energy transfer (LET) than beta emitters.

•       Ac-225 supply constraints represent the critical bottleneck for TAT commercial scaling; multiple governments and private entities are investing in Ac-225 production capacity through Oak Ridge National Laboratory (USA), Canadian Nuclear Laboratories, and European facilities.

•       Bayer's Xofigo (Ra-223 dichloride) — the first approved alpha-emitting radiopharmaceutical — generated USD 415 million in 2023 revenues, demonstrating the commercial viability of alpha therapy in bone metastases.

•       At least 14 Ac-225-labelled agents are currently in clinical trials as of 2024, spanning prostate cancer, neuroendocrine tumours, melanoma, and glioblastoma indications.

Isotope Supply Infrastructure

•       Global Tc-99m supply — produced primarily from Molybdenum-99 (Mo-99) generated in nuclear reactors — remains vulnerable to single-point reactor outages; the 2016 NRU reactor shutdown cost the global diagnostic imaging market an estimated USD 500 million in deferred procedures.

•       SHINE Technologies and NorthStar Medical Radioisotopes are commercialising non-reactor Mo-99/Tc-99m production using neutron capture and proton accelerator technologies, reducing supply chain fragility.

•       The global cyclotron installed base surpassed 1,800 units in 2024, enabling expanded local production of F-18 fluoride and emerging gallium, carbon, and nitrogen PET isotopes.

•       The IAEA's radiopharmaceutical production assistance programs have supported installation of over 60 medical cyclotrons in low- and middle-income countries since 2015, expanding global diagnostic radiopharmaceutical access.

Market Segmentation by Product Type

The nuclear medicine and radiopharmaceutical market is stratified across four primary product categories reflecting the diagnostic-to-therapeutic spectrum of clinical applications.

The diagnostic segment retains revenue leadership driven by the volume of PET/CT and SPECT/CT procedures performed globally — estimated at over 35 million annually in 2024. Therapeutic radiopharmaceuticals, while representing a smaller absolute base, are growing at triple the rate of diagnostics and are projected to achieve revenue parity with the diagnostic segment by approximately 2030, fundamentally reshaping the market composition over the forecast period.

Market Segmentation by Isotope

Isotope selection drives clinical utility, manufacturing complexity, supply chain requirements, and commercial value across the radiopharmaceutical landscape.

Tc-99m retains volume dominance due to its optimal 6-hour half-life, 140 keV gamma energy ideal for SPECT cameras, and the established global Mo-99/Tc-99m generator distribution network. Lu-177 has become the most commercially significant therapeutic isotope, with its 6.7-day half-life and combined beta/gamma emission enabling both targeted therapy delivery and dosimetry verification imaging. The emerging alpha-emitter landscape — Ac-225, At-211, and Bi-213 — represents the market's most significant long-term growth frontier.

Market Segmentation by Application Area

Nuclear medicine serves multiple clinical disciplines, with oncology representing the primary growth engine and neurology emerging as a rapidly expanding frontier.

Oncology's dominance reflects the fundamental alignment between nuclear medicine's molecular targeting capabilities and the precision medicine imperative driving modern cancer care. Neurology is emerging as a high-growth secondary market, propelled by the approval and widespread adoption of amyloid and tau PET imaging agents for Alzheimer's disease diagnosis — a market that did not exist commercially prior to 2012 and now represents a USD 0.7 billion global segment growing at over 18% annually.

Market Segmentation by End-User

The end-user landscape for nuclear medicine products reflects the specialised infrastructure requirements of radiopharmaceutical handling, administration, and monitoring.

Hospitals and academic medical centres maintain their leadership position due to the capital-intensive nature of on-site cyclotron installation, hot lab infrastructure, radiation safety compliance, and the co-location requirements of nuclear medicine imaging and TRT administration suites. The rapid growth of dedicated cancer centres as end-users reflects the institutional prioritisation of TRT programs, requiring specialised dosimetry physics support, dedicated infusion suites with radiation containment, and multidisciplinary theranostics teams.

Regional Market Analysis

Geographic demand distribution reflects differential maturity of nuclear medicine infrastructure, regulatory approval timelines, reimbursement frameworks, and national cancer control strategies.

North America's leadership is underpinned by the world's highest density of PET/CT scanners (approximately 12 per million population vs. a global average of 2.1), a mature reimbursement framework covering both diagnostic and therapeutic nuclear medicine procedures, and the presence of the world's leading radiopharmaceutical commercial infrastructure. Asia-Pacific's exceptional growth reflects China's 14th Five-Year Plan commitment to expanding nuclear medicine capacity to 300 PET centres by 2025, combined with India's National Cancer Grid driving standardisation of molecular imaging in cancer care.

Competitive Landscape

The global nuclear medicine and radiopharmaceutical market has undergone dramatic competitive transformation since 2020, driven by mega-cap pharmaceutical company entry into the TRT space, a wave of radiopharmaceutical M&A activity, and the emergence of well-capitalised specialist theranostics companies. The competitive landscape is bifurcated between the established diagnostic radiopharmaceutical incumbents and the rapidly expanding therapeutic radiopharmaceutical challengers reshaping the industry's commercial gravity.

The defining competitive dynamic of 2022–2024 has been the entry of global pharmaceutical majors — including Eli Lilly's USD 1.4 billion acquisition of Point Biopharma, BMS's USD 4.1 billion acquisition of RayzeBio, and Novartis's sustained investment in the Advanced Accelerator Applications platform — into the radiopharmaceutical space, signalling mainstream pharmaceutical recognition of the sector's blockbuster commercial potential. This M&A wave is expected to continue through 2028 as big pharma builds TRT pipeline depth.

Clinical Pipeline Highlights

The nuclear medicine pipeline is among the most dynamic in all of pharmaceutical development, with over 200 radiopharmaceutical clinical trials registered globally as of 2024. Selected high-impact agents shaping the near-term commercial landscape are presented below.

The pipeline's most strategically significant trend is the systematic expansion of proven theranostic axes — PSMA, SSTR, FAP — into earlier treatment lines and additional cancer histologies, alongside the clinical validation of next-generation alpha-emitting radioligands targeting the same molecular addresses as established beta-emitting agents. FDA Breakthrough Therapy and Priority Review designations have been granted to multiple pipeline agents, indicating regulatory momentum commensurate with the sector's clinical impact.

Key Growth Drivers

Clinical & Epidemiological Drivers

•       Accelerating global cancer burden: 20 million new cases annually (WHO, 2022), with prostate, neuroendocrine, thyroid, and brain cancers representing primary theranostics target populations.

•       Precision oncology imperative: tumour heterogeneity and treatment resistance driving demand for molecular imaging-guided patient selection, with PET-based biomarkers replacing anatomical staging as therapeutic decision tools.

•       Superior clinical outcomes: Lu-177-PSMA-617 demonstrated a 38% reduction in risk of death vs. standard of care in the VISION trial; Lutathera achieved 79% disease control rate in NETTER-1, establishing TRT as a standard-of-care modality.

•       Expanding approved indications: regulatory agencies are broadening approved uses of established agents, with Pluvicto expected to receive approval in hormone-sensitive prostate cancer by 2026, more than doubling its addressable patient population.

Technology & Infrastructure Drivers

•       Digital PET scanner proliferation: total-body PET systems (EXPLORER, uPENNsion) and silicon photomultiplier (SiPM)-based digital PET/CT scanners are improving image quality, reducing scan times, and enabling lower-dose radiopharmaceutical protocols.

•       AI-enhanced dosimetry: machine learning algorithms automating patient-specific dosimetry calculations for TRT are reducing physics support requirements and enabling precision-adapted dosing regimens that maximise tumour dose while protecting normal organs.

•       Radiopharmaceutical CDMO expansion: contract development and manufacturing organisations specialising in radiopharmaceutical production — including Eckert & Ziegler, Isotopia, and TRIUMF Innovations — are scaling capacity to support the pipeline's commercial transition.

•       Radiomics and AI integration: artificial intelligence extracting quantitative imaging biomarkers from nuclear medicine scans is enhancing prognostic value, enabling virtual biopsies, and driving PET-guided therapy personalisation.

Policy & Regulatory Drivers

•       FDA Accelerated Approval and Breakthrough Designation: expedited regulatory pathways are compressing radiopharmaceutical development timelines; Lu-177-PSMA-617 proceeded from Phase I to approval in approximately 4 years.

•       CMS reimbursement expansion: the US Centers for Medicare and Medicaid Services has established dedicated HCPCS codes for multiple novel PET agents and TRT procedures, providing reimbursement certainty that accelerates hospital adoption.

•       IAEA global access programs: the International Atomic Energy Agency's expanded technical cooperation programs are funding cyclotron installation, radiopharmacy establishment, and nuclear medicine specialist training in 40+ lower-income countries.

•       EU Advanced Therapy Medicinal Product (ATMP) framework: regulatory harmonisation across EU member states for radiopharmaceutical approval is reducing time-to-market in the world's second-largest nuclear medicine market.

Market Challenges & Risk Factors

•       Isotope supply chain fragility: the global Tc-99m supply chain's dependence on a small number of ageing nuclear reactors (HFR Petten, BR2 Mol, SAFARI-1) creates systemic supply risk; any single prolonged outage could disrupt millions of diagnostic procedures globally.

•       Ac-225 supply constraint: commercial-scale alpha therapy is bottlenecked by the severe scarcity of Ac-225, currently produced primarily as a decay product of uranium-233 stockpiles at Oak Ridge and from Ra-226 irradiation — a production pathway constrained by both regulatory and radiological safety considerations.

•       Specialised infrastructure requirements: TRT administration requires lead-lined infusion rooms, hot labs, radiation safety officer oversight, and specialised nursing training — capital and personnel requirements that constrain rapid scaling in smaller hospital systems.

•       Cold chain and logistics complexity: short-lived radiopharmaceuticals demand exceptionally rapid distribution logistics; F-18 FDG has a 110-minute half-life requiring just-in-time delivery from regional radiopharmacies to imaging centres.

•       Regulatory complexity: radiopharmaceuticals sit at the intersection of nuclear regulatory authority (NRC/IAEA) and drug regulatory authority (FDA/EMA) oversight, creating dual compliance burdens that extend development timelines and increase costs.

•       Radiation safety perception: public and patient concerns about radiation exposure, despite nuclear medicine procedures typically delivering radiation doses comparable to natural background exposure, continue to create adoption barriers in some markets.

Market Forecast (2024–2032)

The following table presents annual market size projections, year-on-year growth rates, and defining commercial and scientific milestones for the Global Nuclear Medicine and Radiopharmaceutical Market through 2032.

Investment & Strategic Outlook

The nuclear medicine and radiopharmaceutical market presents exceptional investment opportunity across the full value chain, from isotope production infrastructure through clinical-stage biotech to commercial radiopharmacy networks. The sector's investment profile has been transformed by demonstrated blockbuster commercial outcomes and sustained big pharma M&A activity.

M&A & Partnership Activity

•       The USD 4.1 billion BMS acquisition of RayzeBio (January 2024) and USD 1.4 billion Eli Lilly acquisition of Point Biopharma (October 2023) signal mainstream pharmaceutical recognition that radioligand therapy is a durable commercial platform, not a niche speciality.

•       Radiopharmaceutical CDMO and supply infrastructure — cyclotron networks, Mo-99 production, radiopharmacy chains — are attracting private equity investment as essential enablers of the TRT commercial scaling imperative.

•       Isotope production technology companies, particularly those developing non-reactor Tc-99m and novel Ac-225 production methods, represent a high-strategic-value M&A target class for both incumbent producers and emerging TAT developers.

Emerging Investment Frontiers

•       Targeted alpha therapy (TAT): the USD 400M+ Ac-225 supply investment currently underway at national laboratories and private facilities positions the alpha therapy space as the decade's defining pharmaceutical investment theme.

•       Artificial intelligence in radiopharmaceutical development: AI-driven radiochemistry optimisation, automated dosimetry, and PET-derived biomarker development represent a USD 2+ billion incremental opportunity over the forecast period.

•       Global market access: expanding nuclear medicine access in Asia-Pacific, Latin America, and the Middle East represents an incremental USD 5.8 billion opportunity through 2032, targeting currently underserved patient populations with demonstrated clinical need.

•       Combination theranostics: clinical investigation of radioligand therapy combined with checkpoint immunotherapy, PARP inhibitors, and DNA damage response agents is opening new combination product development opportunities commanding premium pricing.

About This Report

This press release summarises findings from Western Market Research Intelligence's flagship publication: Global Nuclear Medicine and Radiopharmaceutical Market — Technology, Pipeline & Forecast, 2024–2032. The full 340-page report provides comprehensive market sizing, granular segmentation across product type, isotope, application, end-user, and geography, a curated clinical pipeline database of 80+ agents, competitive benchmarking of 30+ companies, isotope production infrastructure mapping, regulatory landscape analysis across 25 jurisdictions, and strategic recommendations for radiopharmaceutical developers, investors, hospital procurement executives, and policy makers.

Research Methodology: Rigorous mixed-methods primary research comprising structured interviews with nuclear medicine physicians, radiopharmaceutical chemists, commercial radiopharmacy operators, TRT program directors, isotope production facility managers, pharmaceutical executives, and healthcare investors. Supplemented by secondary data from FDA/EMA regulatory databases, IAEA nuclear medicine programme reports, SNMMI workforce surveys, ClinicalTrials.gov pipeline analysis, and published health economic assessments of nuclear medicine procedures globally.

Media & Analyst Enquiries

Western Market Research Intelligence